Pancreatic Cancer Research

ResearcherJikei University School of MedicineNo recent work listed

Sadamu Homma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5715-3687; OpenAlex author ID A5078965572. Sources: OpenAlex.

Their work

Papers
12 (first author 4, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: none · 2014: 3 papers · 2015: 3 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper

Papers 12

  1. Claudin 7 as a possible novel molecular target for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2018.10.009↗
  2. Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Stud… Co-author DOI 10.1158/2326-6066.cir-17-0386↗
  3. Novel quantitative analysis of the S100P protein combined with endoscopic ultrasound-guided fine needle aspiration cytology in the diagnosis of pancreatic aden… Last author DOI 10.3892/or.2017.5471↗
  4. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcin… Last author DOI 10.1186/s12885-015-1772-1↗
  5. Inhibition of Cell Proliferation and Growth of Pancreatic Cancer by Silencing of Carbohydrate Sulfotransferase 15 In Vitro and in a Xenograft Model. Co-author DOI 10.1371/journal.pone.0142981↗
  6. Prognostic markers for patient outcome following vaccination with multiple MHC Class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for p… Co-author PMID 25550602↗
  7. Wilms tumor gene (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer. Co-author DOI 10.1097/cji.0000000000000020↗
  8. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. First author DOI 10.1158/1078-0432.ccr-14-0314↗
  9. Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. First author DOI 10.4161/21624011.2014.958950↗
  10. Immunotherapy synergizes with chemotherapy targeting pancreatic cancer. First author DOI 10.2217/imt.11.150↗
  11. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response. Last author DOI 10.1007/s00262-011-1033-3↗
  12. Current immunotherapeutic approaches in pancreatic cancer. First author DOI 10.1155/2011/267539↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigeo Koido · 10 shared papers, 2011–2018 · strength 0.37
  2. Haruo Sugiyama · 6 shared papers, 2011–2018 · strength 0.22
  3. Hisao Tajiri · 7 shared papers, 2011–2015 · strength 0.21
  4. Masato Okamoto · 4 shared papers, 2014–2015 · strength 0.16
  5. Kazuki Takakura · 4 shared papers, 2014–2015 · strength 0.16
  6. Shin Kan · 3 shared papers, 2014–2015 · strength 0.12
  7. Mikio Kajihara · 3 shared papers, 2014–2015 · strength 0.12
  8. Sumiyuki Nishida · 3 shared papers, 2011–2018 · strength 0.11
  9. Norimitsu Okui · 1 shared paper, 2019 · strength 0.10
  10. Tadashi Uwagawa · 1 shared paper, 2019 · strength 0.10
  11. Katsuhiko K. Yanaga · 1 shared paper, 2019 · strength 0.10
  12. Akitaka Takahara · 4 shared papers, 2011–2014 · strength 0.10
  13. Hidetoshi Eguchi · 2 shared papers, 2014–2018 · strength 0.09
  14. Hiroaki Nagano · 2 shared papers, 2014–2018 · strength 0.09
  15. Zensho Ito · 2 shared papers, 2015 · strength 0.09
  16. Masafumi Chiba · 1 shared paper, 2017 · strength 0.07
  17. Kazuki Sumiyama · 1 shared paper, 2017 · strength 0.07
  18. Masanori Kon · 1 shared paper, 2018 · strength 0.06
  19. Hiroaki Yanagimoto · 1 shared paper, 2018 · strength 0.06
  20. Mari S. Oba · 1 shared paper, 2018 · strength 0.06
  21. Kei Ito · 1 shared paper, 2018 · strength 0.06
  22. Shinichi Egawa · 1 shared paper, 2018 · strength 0.06
  23. Hideaki Shimada · 1 shared paper, 2018 · strength 0.06
  24. Yoshihide Kanno · 1 shared paper, 2018 · strength 0.06
  25. Takeshi Ishikawa · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.